Sign In
Last checked at 
18 Jun 2021 07:00
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Directorate Change
London, UK, 18 June 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that further to the announcement issued on 28 May 2021, Greg Madison will join the Board with immediate effect and is fulfilling the role of the Group's Chief Executive Officer.
Shield also discloses the following information in accordance with Schedule 2(g) of the AIM Rules for Companies.
Full name: Gregory Paul Madison
Age: 53 years
Current directorships/partnerships:
· American Kidney Fund, Board of Trustees
Previous directorships/partnerships held in the past 5 years:
· Melt Pharmaceuticals, Inc.
· Keryx Biopharmaceuticals, Inc.
· Keryx Biopharma UK Ltd.
Mr Madison currently does not hold any ordinary shares in Shield.
There are no other disclosures required in connection with the appointment of Mr Madison under Schedule Two(g) of the Aim Rules for Companies.
For further information please contact:
Shield Therapeutics plc | www.shieldtherapeutics.com |
Greg Madison, CEO | +44 (0) 191 511 8500 |
Lucy Huntington-Bailey | |
Nominated Adviser and Joint Broker | |
Peel Hunt LLP | |
James Steel/Christopher Golden | +44 (0)20 7418 8900 |
Joint Broker finnCap Ltd Geoff Nash/Alice Lane/George Dollemore |
+44 (0)20 7220 0500 |
Financial PR & IR Advisor |
|
Walbrook PR | +44 (0)20 7933 8780 or shield@walbrookpr.com |
Paul McManus/Lianne Cawthorne |
About Shield Therapeutics plc
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx
Follow the stocks
